

# NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and preferences.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultation with healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines included. Medicines included are consistent across the health board.

## How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

### What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland
  - how well the medicine works,
  - which patients might benefit from it,
  - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
  - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence (NICE) appraisals (NICE MTAs) are applicable in Scotland.

### What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

### Why is a particular medicine not routinely available in NHSGG&C?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board advise the ADTC on their preferred medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

Medicine	Condition being treated	NHSGGC Decision	Date of decision
----------	-------------------------	-----------------	------------------

<b>Abiraterone</b>	Abiraterone acetate plus prednisolone in combination with androgen deprivation therapy for the treatment of high-risk hormone-sensitive non-metastatic prostate cancer (off-label use)	Routinely available in line with local or regional guidance	24/04/2023
NCMAG102		21/08/2023	
<b>Bulevirtide</b>	Treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult patients with compensated liver disease	Routinely available in line with local or regional guidance	24/04/2023
Hepcludex®			
SMC2520			
<b>Burosumab</b>	X-linked hypophosphataemia	Routinely available in line with national guidance	24/04/2023
Crysvita®			
SMC2514			
<b>Casirivimab, Imdevimab</b>	Treatment of acute COVID-19 infection	Not routinely available as not recommended for use in NHSScotland	24/04/2023
Ronapreve®			
SMC2553			
<b>Darolutamide</b>	Treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.	Not routinely available as not recommended for use in NHSScotland	24/04/2023
Nubeqa®			
SMC2544			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Liraglutide</b>  Saxenda® SMC2455	as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of: - ≥30kg/m <sup>2</sup> (obese), or - ≥27kg/m <sup>2</sup> to <30kg/m <sup>2</sup> (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.	Routinely available in line with national guidance	24/04/2023
<b>Nintedanib</b>  Ofev® SMC2513	Treatment of idiopathic pulmonary fibrosis (IPF)	Routinely available in line with national guidance	24/04/2023
<b>Nirmatrelvir, Ritonavir</b>  Paxlovid® SMC2557	Treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19	Routinely available in line with national guidance	24/04/2023
<b>Patiromer sorbitex calcium</b>  Veltassa® SMC2568	Treatment of hyperkalaemia in adults.	Routinely available in line with national guidance	24/04/2023

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Pembrolizumab</b>  Keytruda®  SMC2526	Monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB or IIC melanoma and who have undergone complete resection.	Routinely available in line with local or regional guidance	24/04/2023
<b>Pralsetinib</b>  Gavreto®  SMC2496	Monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor	Routinely available in line with local or regional guidance	24/04/2023
<b>Sotrovimab</b>  Xevudy®  SMC2555	Treatment of symptomatic adults and adolescents (aged 12 years and over and weighing at least 40kg) with acute COVID-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID infection	Routinely available in line with local or regional guidance	24/04/2023
<b>Tocilizumab</b>  RoActemra®  SMC2552	Treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation	Routinely available in line with local or regional guidance	24/04/2023

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Trastuzumab deruxtecan</b>  Enhertu®  SMC2545	Monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.	Routinely available in line with local or regional guidance	24/04/2023
<b>Velmanase alfa</b>  Lamzede®  SMC2466	Enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis	Routinely available in line with national guidance	24/04/2023
<b>Vinorelbine</b>  NCMAG108	As a second- or subsequent-line treatment of patients with malignant pleural mesothelioma whose disease has progressed on or after platinum-based chemotherapy, with or without immunotherapy	Not routinely available as not recommended for use in NHSScotland	24/04/2023